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tiple fibrinogen ligand-receptor interactions that may be
cell-type specific.10-15 For example, exposure of the 15-42
sequence of the Bβ chains of fibrinogen (after release of
fibrinopeptide B) is necessary for the mitogenic stimulation
of anchorage dependent cells, such as endothelial cells and
fibroblasts.12 However, a similar requirement for fi-
brinopeptide B cleavage is not apparent in Raji cells, which
are not anchorage dependent and proliferate in response to
the intact fibrinogen molecule.15 These differences may be
attributed to the interaction of anchorage-dependent cells,
through integrins, with their underlying matrix.
The gross changes in extracellular matrix composition
during intimal lesion development disrupt normal SMC
integrin-matrix interactions, alter intracellular signaling,
and modulate the response of cells to growth promoting
factors.16-18 The ability of polymerized (fibrillar) type 1
collagen to inhibit DNA synthesis and cell prolifera-
tion19,20 has been identified as an important regulatory
factor that maintains a low proliferative index of SMC in
the normal vessel wall. Indeed, inhibition of S-phase entry
by polymeric type I collagen in human aortic SMCs uses
an integrin-dependent signaling mechanism that is redun-
dant in cells grown on monomeric (or soluble) type I col-
lagen.21 The mechanism of SMC proliferation also appears
to depend on the activation of protein kinase A/cyclic
adenosine monophosphate (cAMP) dependent signal-
ing,22 but it is not known whether this signaling is influ-
enced by cell-matrix interactions.
Fibrinogen is a complex plasma protein with a molec-
ular mass of approximately 350 kd that plays a central role
in hemostasis and wound healing.1 Several studies have
indicated that elevated plasma levels of fibrinogen are asso-
ciated with an increased risk of restenosis after angio-
plasty2-4 and intimal lesion development and occlusion in
saphenous vein bypass grafts.5,6 These vascular pathologic
conditions are characterized by rapid smooth muscle cell
(SMC) proliferation and extracellular matrix remodeling.
Fibrinogen can interact directly with SMC in the vessel
wall, because it is deposited within the subendothelium
and media of blood vessels and subjected to a physical
insult, a perturbed shear flow, or both.7-9
Fibrinogen and its various cleavage products can stim-
ulate differential mitogenic responses in fibroblasts,
endothelial cells, and lymphoid cell lines, representing mul-
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Fibrin monomer and fibrinopeptide B act
additively to increase DNA synthesis in smooth
muscle cells cultured from human saphenous vein
Justin Sturge, PhD, Nessa Carey, PhD, Alun H. Davies, DM, and Janet T. Powell, MD, London,
United Kingdom
Purpose: We investigated the hypothesis that fibrinogen increased DNA synthesis (and cell proliferation) of smooth
muscle cells (SMCs) cultured from human saphenous vein and that the increased DNA synthesis was attenuated when
cells were cultured on polymeric collagen.
Methods: SMCs were cultured from human saphenous vein on plastic, fibronectin, monomeric, and polymeric collagen.
Fibrinogen products were prepared by proteolytic digestion. DNA synthesis was measured by bromodeoxyuridine
incorporation into DNA, cell proliferation by cell counting, cyclic adenosine monophosphate by enzyme-linked
immunosorbent assay, and fibrinopeptide B labeled with iodine 125 used for binding studies.
Results: Fibrin monomer (0.003-0.1 µmol/L) stimulated a concentration-dependent increase in DNA synthesis of up
to 10-fold, which could be inhibited by the peptide Bβ15-42. The stimulation of DNA synthesis was highest for cells
cultured on plastic and lowest for cells cultured on type I collagen polymer. Much higher concentrations of fibrinogen
(0.3-1 µmol/L) were required to effect similar increases in DNA synthesis. Fibrinogen had a particular effect to aug-
ment DNA synthesis, up to 14-fold, when cells were cultured on monomeric type I collagen. This augmented DNA
synthesis was inhibited by a neutralizing antibody to urokinase-type plasminogen activator. Incubation of cells cultured
on collagen monomer with fibrinogen resulted in production of fibrinopeptide B. Fibrinopeptide B (5 µmol/L)
increased DNA synthesis by fourfold and had additive effects with fibrin monomer to increase DNA synthesis.
Iodinated tyrosine fibrinopeptide B bound to SMCs (dissociation constant 0.6 µmol/L).
Conclusion: Cultured human saphenous vein SMCs appear to have high-affinity receptors for fibrin monomer and fi-
brinopeptide B, the engagement of which stimulates DNA synthesis. These mechanisms may be pertinent to the asso-
ciation between fibrinogen and vein graft stenosis in vivo. (J Vasc Surg 2001;33:847-53.)
Here we demonstrate that fibrinogen and some of its
specific degradation products act as potent stimulators of
DNA synthesis in cultured human vascular SMCs. We also
indicate the potential role of the extracellular matrix in
regulating the cellular response to fibrinogen.
MATERIALS AND METHODS
Cell culture. Saphenous vein was obtained from
patients undergoing cardiovascular surgery at Imperial
College, London, United Kingdom. For the studies
described, veins were obtained from 18 separate donors,
undergoing either coronary artery bypass (13) or
femorodistal bypass (5) grafting, with approval of the
Riverside Research Ethics Committee. Human saphenous
vein SMC cultures were established by a modified version
of the standard explant method.23 Cells were cultured on
either uncoated plastic or plastic coated with fibronectin,
monomeric collagen, or polymeric collagen. Full details of
the culture methods, preparation of fibrinogen and its
cleavage products, measurement of DNA synthesis, cAMP,
binding assays, and sources of reagents and peptides are
given in the Appendix. DNA synthesis was measured by
bromodeoxyuridine (BrdU) incorporation, cAMP was
measured by immunoassay, and fibrinopeptides were
quantified by capillary zone electrophoresis and radiola-
beled with iodine 125.
Data analysis. The Student paired and unpaired t
tests were used for comparison between experimental
data points in all experiments.
RESULTS
Fibrinogen and soluble fibrin monomer stimulation
of DNA synthesis in human saphenous vein SMCs.
When cells were cultured on uncoated plastic, both fibrino-
gen and fibrin monomer stimulated DNA synthesis to a
maximum of about 10-fold, although the concentration of
fibrin monomer (0.03 µmol/L) required for peak DNA
synthesis was less than the concentration of fibrinogen (Fig
1). Similar increases in DNA synthesis were observed when
three commercial separate sources of fibrinogen, including
one designated as thrombin free, were used. In contrast, the
complex of the fibrinogen degradation products fragment
D and fragment E had only a weak effect on DNA synthe-
sis (data not shown), and bovine serum albumin (up to 4
µmol/L) had no effect (Fig 1). At concentrations lower
than 1.0 µmol/L, fragment D and fragment E complex did
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Fig 1. Fibrinogen and fibrin stimulation of DNA synthesis in SMCs cultured from human saphenous vein. Cells were cultured on
uncoated plastic, and protein was added for 24 hours before measurement of DNA synthesis (BrdU incorporation). Results (mean ± SD)
are reported as percentage DNA synthesis in comparison with controls with no added protein.
Table I. Effect of different proteins on cell proliferation
Cell number (× 10–3) after 72 h
Basal 3 µmol/L BSA 0.3 µmol/L 0.3 µmol/L fibrin 0.1 µmol/L PDGF 1 U/mL thrombin
fibrinogen monomer + 0.3 µmol/L BSA + 0.3 µmol/L BSA
32 ± 4 39 ± 6 58 ± 11* 67 ± 19* 70 ± 13* 46 ± 7*
Cells (25 × 103) were cultured on uncoated plastic; results show mean ± SD of six replicate wells. 
*Significant increase compared either with cells cultured in serum-free medium alone (basal) or in the presence of 3 mmol/L BSA, ANOVA P < .03.
ANOVA, Analysis of variance; BSA, bovine serum albumin; PDGF, platelet-derived growth factor. 
not stimulate DNA synthesis. At 1.0 µmol/L fragment D
and fragment E complex only stimulated a fourfold increase
and at 3.0 µmol/L only stimulated a twofold increase in
DNA synthesis (data not shown). Similarly, incubation of
cells for 72 hours with either fibrinogen or fibrin monomer
increased cell proliferation, in comparison to bovine serum
albumin (Table I). Fibrin monomer was produced with
thrombin (final concentration < 0.05 U/mL). This con-
centration of thrombin had no effect on DNA synthesis in
cultured SMCs: even when used at 1 U/mL thrombin only
stimulated a maximum twofold increase in DNA synthesis
(data not shown) and a modest increase in cell number
(Table I). Preincubation of cells with thrombin inhibitors,
either hirudin (2 U/mL) or PPACK (phenylalanyl-L-
prolyl-L-arginyl-chlormomethylketone) (1 µmol/L) did
not alter the concentration-dependent increase in DNA
synthesis in response to fibrinogen. The fibrin polymeriza-
tion inhibitor GPRP (glycine-proline-arginine-proline)
(0.01-3.0 mmol/L) did not alter DNA synthesis stimulated
by fibrin monomer. Therefore, it appeared likely that both
fibrin monomer and fibrinogen could stimulate DNA syn-
thesis in SMCs cultured from human saphenous vein.
Incubation of cells with 0.3 µmol/L fibrinogen resulted in
a significant decrease in cellular cAMP concentration, to
0.94 ± 0.21 pmol per million cells compared with 1.60 ±
0.15 in the absence of fibrinogen (n = 4, P < .05). In con-
trast, incubation of cells with fibrin monomer (0.03
µmol/L) had no effect on cAMP concentration.
Fibrinogen stimulation of DNA synthesis on colla-
gen monomer, collagen polymer, and fibronectin.
Concurring with previous studies,19-21 culture of SMCs on
type I collagen polymer inhibited serum-stimulated DNA
synthesis by about 50% compared with culture on uncoated
plastic. Therefore, DNA synthesis was adjusted to the per-
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centage basal levels measured on each particular matrix.
The concentration-dependent effects of fibrinogen on
increased DNA synthesis were reduced when SMCs were
cultured on plastic coated with either collagen polymer or
fibronectin, with 0.3 µmol/L fibrinogen stimulating only a
fourfold to sixfold increase in DNA synthesis. Again, inclu-
sion of either PPACK (1 µmol/L) or hirudin (2 U/mL) in
the culture medium did not alter the response. Similarly,
fibrin monomer only stimulated a maximum fourfold to six-
fold increase in DNA synthesis when SMCs were cultured
on either collagen polymer or fibronectin. However, the
shape of the concentration-response curves was similar to
that for SMCs cultured on plastic (the data for cells cultured
on fibronectin are shown in Fig 2). In contrast, when SMCs
were cultured on collagen monomer, the response to fibrin-
ogen, but not to fibrin monomer, was altered markedly (Fig
3). However, the inclusion of PPACK in the culture media
returned the concentration-response curve to one similar to
the curves on fibronectin (Figs 2 and 3). PPACK did not
alter fibrinogen-mediated increases in DNA synthesis when
SMCs were cultured on plastic, fibronectin, or collagen
polymer. Parallel to the results for SMC cultured on
uncoated plastic, fibrinogen, but not fibrin monomer,
caused a significant 35% decrease in the concentration of
cAMP of cells cultured on collagen monomer. The basal
concentration of cAMP, 1.55 ± 0.2 pmol per million cells,
was unchanged 30 minutes after the addition of 0.1
µmol/L fibrin monomer but decreased to 1.05 ± 0.1 pmol
per million cells after addition of 0.1 µmol/L fibrinogen (P
< .05, n = 4).
The role of fibrinopeptide cleavage for cells cul-
tured on collagen monomer. To investigate whether the
enhanced response to fibrinogen for SMCs cultured on
collagen monomer depended on a cell-associated serine
Fig 2. Stimulation of DNA synthesis in SMCs by fibrinogen and fibrin monomer for cells on fibronectin. Cells were cultured on
fibronectin-coated plastic, and protein was added for 24 hours before measurement of DNA synthesis (BrdU incorporation). Results
(mean ± SD) are reported as percentage DNA synthesis in comparison with controls with no added protein. Results for cells cultured
on type I collagen polymer were almost identical, with superimposed curves.
protease, we included hirudin (a thrombin inhibitor)
amiloride (which inhibits urokinase-type plasminogen
activator [u-PA]) and benzamidine (a general serine pro-
tease inhibitor) in the SMC culture medium. None of
these compounds altered DNA synthesis in the absence of
fibrinogen. The presence of amiloride (10 µmol/L) sig-
nificantly inhibited DNA synthesis stimulated by fibrino-
gen (0.03-0.3 µmol/L) in cells cultured on type I
collagen monomer, but had no effect on DNA synthesis
stimulated by similar concentrations of fibrinogen in cells
cultured on type I collagen polymer (0.3 µmol/L fibrino-
gen, Table II). Benzamidine (1 mmol/L) also significantly
inhibited DNA synthesis stimulated by fibrinogen (0.1-
0.3 µmol/L) in cells cultured on type I collagen monomer
but had no effect on DNA synthesis stimulated by similar
concentrations of fibrinogen in cells cultured on type I
collagen polymer (0.3 µmol/L fibrinogen, Table I).
Hirudin did not alter the fibrinogen-mediated stimulation
of DNA synthesis. The significant effect of amiloride sug-
gested the involvement of u-PA. A neutralizing antibody
to u-PA (10 µg mL–1) significantly inhibited DNA syn-
thesis stimulated by fibrinogen (0.1-0.3 µmol/L) in cells
cultured on monomeric but not polymeric type I collagen
(Table II), whereas an isotype-matched antibody
(anti–monocyte chemoattractant protein-1 [anti-MCP-
1]) had no effect. Taken together, these results indicate
that u-PA is actively involved in the additional DNA syn-
thesis stimulated by fibrinogen in cells cultured on type I
collagen monomer.
Because u-PA has been shown to release fibrinopep-
tide B from fibrinogen in vitro,24 we measured fibrino-
peptide B accumulation in the conditioned culture
medium of cells incubated with fibrinogen, using capillary
zone electrophoresis. Fibrinopeptide B generation was sig-
nificantly higher in cells grown on type I collagen
monomer compared with plastic (0.77 ± 0.06 µmol/L
and 0.43 ± 0.08 µmol/L, respectively at 3 µmol/L fibrin-
ogen, P < .05). Fibrinopeptide A remained below the lim-
its of detection. The presence of amiloride (10 µmol/L)
inhibited fibrinopeptide B accumulation in the condi-
tioned medium of cells grown on type I collagen
monomer to levels below the detection limits of the assay
in the presence of 1 µmol/L fibrinogen and to 0.16 ±
0.09 µmol/L in the presence of 3 µmol/L fibrinogen.
These findings imply that when human saphenous vein
SMCs are cultured on collagen monomer there is
enhanced u-PA activity, which permits the cleavage of fi-
brinopeptide B from fibrinogen.
Fibrinopeptide B and stimulation of DNA synthe-
sis in human saphenous vein SMCs. Fibrinopeptide 
B (1-10 µmol/L) stimulated DNA synthesis in SMCs to 
a maximum of fivefold, and results were similar for cells
cultured on uncoated plastic, fibronectin collagen poly-
mer, or monomer (data not shown). The tyrosine deriva-
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Fig 3. Inhibition of the fibrinogen-mediated stimulation of DNA synthesis for SMCs cultured on monomeric collagen. Cells have been
cultured on plastic coated with collagen monomer, and protein was added for 24 hours before measurement of DNA synthesis (BrdU
uptake). Amiloride was used at 10 µmol/L and PPACK at 1 µmol/L. Results (mean ± SD) are reported as percentage DNA synthesis
in comparison with controls with no added protein.
Table II. Effect of u-PA inhibition on fibrinogen-stimu-
lated DNA synthesis in SMCs cultured on type collagen
monomer and polymer
Monomeric Polymeric
Substratum type I collagen type I collagen
Basal (no fibrinogen) 100 100
Fibrinogen (0.3 µmol/L) 710 ± 117 390 ± 120
+Amiloride 275 ± 21 290 ± 95
+Benzamidine 460 ± 158 395 ± 115
+Anti–u-PA 485 ± 62 415 ± 75
+Anti–MCP-1 805 ± 130 460 ± 67
DNA synthesis is reported as percentage of basal levels in the absence of added
fibrinogen. Results (mean ± SD) are from four to eight separate experiments.
tive of fibrinopeptide B (fibrinopeptide B-tyr) had a simi-
lar concentration-dependent effect on DNA synthesis as
fibrinopeptide B (data not shown). Fibrinopeptide B (5
µmol/L) did not appear to alter the cellular cAMP con-
centration. Fibrinopeptide B, but not fibrinopeptide A,
and fibrin monomer showed additive effects to increase
DNA synthesis in human saphenous vein SMCs cultured
on type I collagen monomer (Table III). Separately, fibrin
monomer (0.3 µmol/L) and fibrinopeptide B (5 µmol/L)
stimulated fivefold and fourfold increases in DNA synthe-
sis respectively; together a ninefold increase was observed
(Table III). In contrast, fibrinopeptide B and fibrinogen
(0.01-1.0 µmol/L), in the presence of PPACK, did not
have additive effects (Table III). Similar additive effects of
fibrinopeptide B and fibrin monomer were observed for
cells cultured on plastic and fibronectin, but not for cells
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cultured on type I collagen polymer. These experiments
strongly suggest that human saphenous vein SMCs have
specific receptors for both fibrin monomer and fi-
brinopeptide B, the engagement of which stimulates DNA
synthesis. Experiments with [125I]fibrinopeptide B-tyr
were performed to clarify whether fibrinopeptide B bound
to SMCs. Like fibrinopeptide B, fibrinopeptide B-tyr stim-
ulated DNA synthesis in SMCs. Saturable binding of
[125I]fibrinopeptide B-tyr peptide to confluent monolay-
ers of SMCs cultured on plastic was demonstrated, an
apparent dissociation constant (Kd) of 0.6 µmol/L at 4°C
(Fig 4). The binding of fibrinopeptide B-tyr was reversed
by a 100-fold molar excess of fibrinopeptide B.
Competition experiments with fibrinogen were restricted
by the limited solubility of this protein. Scatchard plot
analysis (Fig 4, inset) indicates the presence of a single-
Table III. The effects of fibrin monomer and fibrinopeptide B on DNA synthesis in SMCs cultured on different substrata
DNA synthesis (% control)
Substratum Plastic Fibronectin Collagen monomer Collagen polymer
Fibrinopeptide B (5 µmol/L) 387 ± 108 412 ± 146 485 ± 96 306 ± 155
Fibrinogen (3 µmol/L) 759 ± 178 411 ± 92 515 ± 93 433 ± 46
Fibrinogen (3 µmol/L) + FPB 746 ± 95 435 ± 76 508 ± 78 448 ± 80
Fibrin monomer (0.3 µmol/L) 834 ± 213 447 ± 92 535 ± 64 393 ± 141
Fibrin monomer (0.3 µmol/L) + FPB 1154 ± 188* 856 ± 105* 930 ± 233* 402 ± 126
Fibrin monomer (0.3 µmol/L) + FPA 636 ± 121 493 ± 202 358 ± 104 306 ± 155
Results (mean ± SD) are from 3-15 separate experiments. All experiments using fibrinogen were carried out in the presence of 1 µmol/L PPACK.
*Significantly higher than for fibrin monomer only, P < .02, paired t test.
FPB, Fibrinopeptide B at 5 µmol/L; FPA, fibrinopeptide A at 5 µmol/L; SMC, smooth muscle cell.
Fig 4. The binding of labeled fibrinopeptide B to SMCs cultured from human saphenous vein. Iodinated fibrinopeptide B-tyr was incu-
bated at 4°C with confluent monolayers of SMCs cultured on uncoated plastic. Results show saturable binding (mean ± SD for 5-6
wells). Scatchard plot (inset) suggests presence of a single, high-affinity, binding site, with an apparent Kd of 0.6 µmol/L calculated from
binding curve. B (tyr), Tyrosine derivative of fibrinopeptide B.
binding site for fibrinopeptide B-tyr on SMCs cultured
from human saphenous vein. The binding experiment
shown in Fig 4 was repeated once, with similar results (Kd
0.65 µmol/L).
Inhibition of fibrin-mediated increases in DNA
synthesis. In contrast to fibrinopeptide B, the peptides
RGDV, γ3, Bβ15-42, or a scrambled isomer of the peptide
Bβ15-42 at low concentrations (10 µmol/L) had no
effect on DNA synthesis of SMCs. At high concentrations
(50 µmol/L), Bβ15-42 and its scrambled isomer increased
DNA synthesis by up to 50%. Only Bβ15-42 (50 µmol/L)
significantly inhibited (by 30%-40%) the effect of fibrin
monomer (0.03-0.1 µmol/L) to increase DNA synthesis
and cell proliferation (data given in Appendix, online only).
This peptide (50 µmol/L) had a negligible effect on fibrin-
ogen-stimulated DNA synthesis.
The effect of fibrinogen and its products on DNA
synthesis in saphenous vein SMCs. A summary of the
effects of all the different fibrinogen products on DNA
synthesis and cellular cAMP concentration is given in
Table IV.
DISCUSSION
This is the first study to report that fibrin monomer
has potent effects on DNA synthesis and cell proliferation
in human vascular SMCs, although previous studies have
shown similar effects in rabbit SMCs.25 Moreover, fi-
brinopeptide B and fibrin monomer have additive effects
to increase, by an order of magnitude, DNA synthesis in
SMCs cultured from human saphenous vein. Fibrinogen
also increased DNA synthesis, but much higher concen-
trations were required than of fibrin monomer. These
findings suggest a possible mechanism underlying the
association of increased plasma concentrations of fibrin-
ogen with restenosis after angioplasty and vein graft steno-
sis, with intimal SMC proliferation being an essential
feature of both pathologic conditions. The generation of
fibrin monomer and fibrinopeptide B close to the surface
of SMCs may arise through either thrombin activity or the
activity of enzymes such as u-PA, at the cell surface. We
also provide evidence that, in cultured SMCs, cell-derived
u-PA degrades fibrinogen and generates products with
enhanced effects on the stimulation of DNA synthesis.
The modulation of these processes by the extracellular
matrix is in keeping with the situation in intimal hyperpla-
sia, where SMCs of a synthetic phenotype proliferate in an
amorphous matrix that is likely to include soluble collagen
and collagen degradation products.
It is unlikely that our findings are confounded by the
possibility that fibrinogen preparations were contaminated
with mitogens such as thrombin or basic fibroblast growth
factor.26 First, thrombin, even at concentrations of 1
U/mL, only stimulated DNA synthesis in SMCs cultured
from saphenous vein by a maximum of twofold. Second,
the binding of basic fibroblast growth factor to fibrinogen
and fibrin monomer is similar,26 but we observed that
fibrin monomer was 10- to 100-fold more potent as a
mitogen for SMCs compared with fibrinogen (Figs 1 and
2). Moreover, the effects of fibrin monomer could be
selectively inhibited by the peptide derived from the newly
exposed aminoterminus of the Bβ fibrinogen chains,
Bβ15-42. This latter observation also indicates the pres-
ence of specific receptors for fibrin monomer on the SMC
plasma membrane. The possible involvement of the Bβ15-
42 sequence of fibrin monomer is strengthened by two
further observations. First, the fibrinogen fragment com-
plex fragment D and fragment E, which lacks the Bβ15-42
sequence, had no effect to increase DNA synthesis.
Second, a scrambled isomer of the peptide Bβ15-42 did
not inhibit fibrin-mediated increases in DNA synthesis.
The SMC receptor for the Bβ15-42 epitope of fibrin
monomer will be investigated in future studies.
The remarkable increase in DNA synthesis stimulated
by fibrinogen for cells cultured on collagen monomer
revealed a possible mechanism relevant to the proliferation
of vascular SMCs in intimal lesions in vivo. The altered
extracellular matrix associated with vascular injury (increase
in soluble type I collagen and decrease in fibrillar type I col-
lagen) is known to be important in the regulation of vas-
cular SMC growth in response to various mitogenic
stimuli.21 In vitro it has been shown that the enzyme u-PA
can directly cleave fibrinopeptide B, but not fibrinopeptide
A, from fibrinogen.24 Inhibitors of u-PA (amiloride, ben-
zamidine, and anti–u-PA antibodies) inhibited fibrinogen-
stimulated DNA synthesis by 35% to 60% in cells cultured
on type I collagen monomer but on no other substrata and
prevented the accumulation of fibrinopeptide B. These
findings indicate that the activity of SMC u-PA is increased
when cells are cultured on collagen monomer.
We did not use scrambled peptides of fibrinopeptide B
to determine whether its mitogenic effects on SMCs were
specific. However, we have determined that fibrinopeptide
B has a single-receptor binding site on human saphenous
vein SMCs with a binding affinity (Kd = 0.6 µmol/L),
similar to the concentration of fibrinopeptide B released
from fibrinogen by cells cultured on collagen monomer.
Fibrinopeptide B has been reported previously to have
mitogenic properties, but without firm evidence for the
presence of a cellular receptor for this fibrinogen degrada-
tion product.11,27,28 Moreover, fibrinopeptide B (but not
fibrinopeptide A) and fibrin monomer had additive effects
on DNA synthesis for cells cultured on fibronectin, colla-
gen monomer, or uncoated plastic.
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Table IV. Summary results
Stimulation Cellular
Fibrinogen/derivative of DNA synthesis cAMP
Fibrinogen ↑↑ (P, CP, F) ↑
↑↑↑↑ (CM)
Fragment D, fragment E ↑ (P, CM) ND
Fibrin monomer ↑↑ (P, CM, CP, AN) ↔
Fibrinopeptide B ↑↑ (P, CM) ↔
cAMP, cyclic adenosine monophosphate; CM, Collagen monomer; CP, col-
lagen polymer; F, fibronectin; ND, not determined; P, uncoated plastic.
In summary, we have shown that fibrin monomer is a
potent mitogen for vascular SMCs cultured from human
saphenous vein. These cells also appear to have receptors for
fibrinopeptide B, the engagement of which provides for the
additive effects of this peptide and fibrin monomer to aug-
ment DNA synthesis. We have described these effects using
cultured cells, but similar mechanisms could be important
to the development of intimal hyperplasia in vivo.
We thank all the cardiac and vascular surgeons of the
Hammersmith Hospitals Trust for saphenous vein. We
also thank Keith Jones and Justine Reise for help with
some of the bromodeoxyuridine experiments.
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